[{"id":"a4f49e7e-9276-4f99-a3a9-4ffebacbb6c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01915602","created_at":"2021-01-18T08:38:22.715Z","updated_at":"2025-02-25T17:06:57.633Z","phase":"Phase 2","brief_title":"Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT01915602","lead_sponsor":"Bayer","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" NRAS mutation • RAS mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • refametinib (BAY86-9766)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/27/2013","start_date":" 09/27/2013","primary_txt":" Primary completion: 07/29/2015","primary_completion_date":" 07/29/2015","study_txt":" Completion: 02/08/2017","study_completion_date":" 02/08/2017","last_update_posted":"2021-04-08"},{"id":"c676ad83-3cce-4dbc-9387-cd84426fb1c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01915589","created_at":"2021-01-18T08:38:21.271Z","updated_at":"2025-02-25T17:06:57.058Z","phase":"Phase 2","brief_title":"Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT01915589","lead_sponsor":"Bayer","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" NRAS mutation • RAS mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e refametinib (BAY86-9766)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 09/16/2013","start_date":" 09/16/2013","primary_txt":" Primary completion: 10/08/2014","primary_completion_date":" 10/08/2014","study_txt":" Completion: 10/08/2014","study_completion_date":" 10/08/2014","last_update_posted":"2021-04-08"}]